P. Fuchs

发表

Precision and Accuracy of Fluconazole Susceptibility Testing by Broth Microdilution, Etest, and Disk Diffusion Methods

M. Pfaller, R. Rennie, A. Barry, 2002, Antimicrobial Agents and Chemotherapy.

Interpretive criteria for disk diffusion susceptibility testing of mupirocin, a topical antibiotic

R. Jones, A. Barry, P. Fuchs, 1990, Journal of clinical microbiology.

In vitro activity of ceftizoxime, ceftazidime, cefuroxime, ceftriaxone, cefotaxime, and penicillin againstStreptococcus pneumoniae as determined by three quantitative methods

A. Barry, P. Fuchs, S. Brown, 1996, European Journal of Clinical Microbiology and Infectious Diseases.

In vitro activity of an orally administered streptogramin (RPR 106,972) compared to quinupristin/dalfopristin and erythromycin

A. Barry, P. Fuchs, S. Brown, 1997, European Journal of Clinical Microbiology and Infectious Diseases.

Comparative antimicrobial activity of piperacillin-tazobactam tested against more than 5000 recent clinical isolates from five medical centers. A reevaluation after five years.

R. Jones, K. Aldridge, S. Marshall, 1995, Diagnostic microbiology and infectious disease.

Prosthetic Valve Endocarditis Resulting from Nosocomial Bacteremia: A Prospective, Multicenter Study

V L Yu, A Goetz, E. Wong, 1993, Annals of Internal Medicine.

Prosthetic valve endocarditis: superiority of surgical valve replacement versus medical therapy only.

E. Wong, V. Yu, L. Gentry, 1994, The Annals of thoracic surgery.

In Vitro Antimicrobial Activity of MSI-78, a Magainin Analog

Steven D. Brown, A. Barry, P. Fuchs, 1998, Antimicrobial Agents and Chemotherapy.

In vitro activity of the new ketolide HMR 3004 compared to an azalide and macrolides againstStreptococcus pneumoniae andHaemophilus influenzae

A. Barry, P. Fuchs, S. Brown, 1997, European Journal of Clinical Microbiology and Infectious Diseases.

Antimicrobial prophylaxis in elective colon surgery. Experience of 1,035 operations in a community hospital.

P. Fuchs, M. Gustafson, J. Peck, 1984, American journal of surgery.

Proposed disk diffusion susceptibility criteria for ofloxacin

R. Jones, A. Barry, P. Fuchs, 1985, Journal of clinical microbiology.

In vitro evaluation of cefixime (FK027, FR17027, CL284635): spectrum against recent clinical isolates, comparative antimicrobial activity, beta-lactamase stability, and preliminary susceptibility testing criteria.

L. Ayers, R. Jones, A. Barry, 1986, Diagnostic microbiology and infectious disease.

Identification of β-Lactamase-Negative, Ampicillin-Resistant Strains of Haemophilus influenzae with Four Methods and Eight Media

Steven D. Brown, A. Barry, P. Fuchs, 2001, Antimicrobial Agents and Chemotherapy.

In vitro activity of ticarcillin plus clavulanic acid against 632 clinical isolates

R. Jones, A. Barry, P. Fuchs, 1984, Antimicrobial Agents and Chemotherapy.

Susceptibility ofHaemophilus influenzae to clarithromycin alone and in combination with its 14-hydroxy metabolite

A. Barry, P. Fuchs, M. Pfaller, 1991, European Journal of Clinical Microbiology and Infectious Diseases.

In vitro activity of telithromycin against Streptococcus pneumoniae resistant to other antibiotics, including cefotaxime.

Steven D. Brown, A. Barry, P. Fuchs, 2002, The Journal of antimicrobial chemotherapy.

Antipneumococcal Activities of a Ketolide (HMR 3647), a Streptogramin (Quinupristin-Dalfopristin), a Macrolide (Erythromycin), and a Lincosamide (Clindamycin)

A. Barry, P. Fuchs, S. Brown, 1998, Antimicrobial Agents and Chemotherapy.

Susceptibility of multi-resistant Streptococcus pneumoniae to ciprofloxacin, ofloxacin and levofloxacin.

A. Barry, P. Fuchs, S. Brown, 1997, The Journal of antimicrobial chemotherapy.

In Vitro Activities of Ertapenem (MK-0826) against Clinical Bacterial Isolates from 11 North American Medical Centers

Steven D. Brown, A. Barry, P. Fuchs, 2001, Antimicrobial Agents and Chemotherapy.

Tentative interpretive criteria for testing the susceptibility of Streptococcus pneumoniae to eight fluoroquinolones.

A. Barry, P. Fuchs, S. Brown, 1996, Diagnostic microbiology and infectious disease.

In Vitro Activity of the Ketolide ABT-773

Steven D. Brown, A. Barry, P. Fuchs, 2001, Antimicrobial Agents and Chemotherapy.

Interpretive criteria and quality control parameters for testing of susceptibilities of Haemophilus influenzae and Streptococcus pneumoniae to trimethoprim and trimethoprim-sulfamethoxazole. The Antimicrobial Susceptibility Testing OC Group

A. Barry, P. Fuchs, S. Brown, 1997, Journal of clinical microbiology.

Interpretive criteria for temocillin disk diffusion susceptibility testing

R. Jones, A. Barry, P. Fuchs, 1985, European Journal of Clinical Microbiology.

Cerebellar toxicity following high-dose cytosine arabinoside.

L. Zivin, R. Goldman, P. Fuchs, 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Ampicillin-sulbactam susceptibility testing criteria

D. Hardy, P. Fuchs, M. Pfaller, 1993, European Journal of Clinical Microbiology and Infectious Diseases.

Significance of Nosocomial Infection Rates in the Era of DRGs

P. Fuchs, M. Gustafson, 1986, Infection Control.

Epidemiology of hospital-associated infections

P. Fuchs, 1979 .

Neonatal relapsing fever due to transplacental transmission of Borrelia.

P. Fuchs, A. Oyama, 1969, JAMA.

Standardization of disk diffusion and agar dilution susceptibility tests for Neisseria gonorrhoeae: interpretive criteria and quality control guidelines for ceftriaxone, penicillin, spectinomycin, and tetracycline

P. Murray, R. Jones, J. Washington, 1989, Journal of clinical microbiology.

Identification and Antimicrobial Susceptibility of 250 Bacteroides fragilis Subspecies Tested by Broth Microdilution Methods

Ronald N. Jones, P. Fuchs, 1976, Antimicrobial Agents and Chemotherapy.

Prosthetic Valve Endocarditis Resulting from Nosocomial Bacteremia

E. Wong, V. Yu, L. Gentry, 2013 .

In vitro activity of temafloxacin against gram-positive cocci including methicillin-resistant Staphylococcus aureus.

P. Fuchs, 1991, The American journal of medicine.

In vitro activities of a streptogramin (RP59500), three macrolides, and an azalide against four respiratory tract pathogens

A. Barry, P. Fuchs, 1995, Antimicrobial agents and chemotherapy.

Cefuroxime, a New Parenteral Cephalosporin: Collaborative In Vitro Susceptibility Comparison with Cephalothin Against 5,887 Clinical Bacterial Isolates

Ronald N. Jones, A. Barry, P. Fuchs, 1977, Antimicrobial Agents and Chemotherapy.

Susceptibility to RPR 106,972, quinupristin/dalfopristin and erythromycin among recent clinical isolates of enterococci, staphylococci and streptococci from North American medical centres.

A. Barry, P. Fuchs, S. Brown, 1998, The Journal of antimicrobial chemotherapy.

In vitro activities of 12 orally administered antimicrobial agents against four species of bacterial respiratory pathogens from U.S. Medical Centers in 1992 and 1993

A. Barry, P. Fuchs, M. Pfaller, 1994, Antimicrobial Agents and Chemotherapy.

In Vitro Activities of the Ketolide HMR 3647 against Recent Gram-Positive Clinical Isolates and Haemophilus influenzae

Steven D. Brown, A. Barry, P. Fuchs, 1998, Antimicrobial Agents and Chemotherapy.

In Vitro Antimicrobial Activity of Cinoxacin Against 2,968 Clinical Bacterial Isolates

R. Jones, P. Fuchs, 1976, Antimicrobial Agents and Chemotherapy.

In vitro activity of trovafloxacin against ciprofloxacin-susceptible and -resistant clinical bacterial isolates and assessment of the trovafloxacin disk test.

A. Barry, P. Fuchs, S. Brown, 1999, Diagnostic microbiology and infectious disease.

Multicenter in vitro evaluation of SM-7338, a new carbapenem

R. Jones, K. Aldridge, A. Barry, 1989, Antimicrobial Agents and Chemotherapy.

Comparative antimicrobial activities of the penem WY-49605 (SUN5555) against recent clinical isolates from five U.S. medical centers

P. Fuchs, M. Pfaller, S. Allen, 1995, Antimicrobial agents and chemotherapy.

In vitro activity of FCE 22101, imipenem, and ceftazidime against over 6,000 bacterial isolates and MIC quality control limits of FCE 22101

R. Jones, K. Aldridge, A. Barry, 1988, European Journal of Clinical Microbiology and Infectious Diseases.

In-vitro selection of quinolone-resistant staphylococcal mutants by a single exposure to ciprofloxacin or trovafloxacin (CP-99,219) -letter-.

A. Barry, P. Fuchs, S. Brown, 1996, The Journal of antimicrobial chemotherapy.

Provisional interpretive criteria for quinupristin/dalfopristin susceptibility tests.

A. Barry, P. Fuchs, S. Brown, 1997, The Journal of antimicrobial chemotherapy.

Interpretive criteria and quality control for antimicrobial susceptibility tests of levofloxacin

F. Tenover, L. Reller, J. Jorgensen, 1994, European Journal of Clinical Microbiology and Infectious Diseases.

RP 59500, a new streptogramin highly active against recent isolates of North American staphylococci.

C. Stratton, G. Archer, P. Murray, 1993, Diagnostic microbiology and infectious disease.

Interactions of Quinupristin-Dalfopristin with Eight Other Antibiotics as Measured by Time-Kill Studies with 10 Strains of Staphylococcus aureus for Which Quinupristin-Dalfopristin Alone Was Not Bactericidal

Steven D. Brown, A. Barry, P. Fuchs, 2001, Antimicrobial Agents and Chemotherapy.

Bactericidal Activity of Quinupristin-Dalfopristin against Staphylococcus aureus: Clindamycin Susceptibility as a Surrogate Indicator

Steven D. Brown, A. Barry, P. Fuchs, 2000, Antimicrobial Agents and Chemotherapy.

Provisional quality control parameters and interpretive criteria for testing susceptibility ofStreptococcus pneumoniae andHaemophilus influenzae to quinupristin/dalfopristin (RP59500)

P. Fuchs, S. Brown, A. Barry, 1998, European Journal of Clinical Microbiology and Infectious Diseases.

In-vitro antimicrobial activity of a carbapenem, MK-0826 (L-749,345) and provisional interpretive criteria for disc tests.

A. Barry, P. Fuchs, S. Brown, 1999, The Journal of antimicrobial chemotherapy.

Surrogate disks for predicting cefotaxime and ceftriaxone susceptibilities of Streptococcus pneumoniae

A. Barry, P. Fuchs, 1996, Journal of clinical microbiology.

Reassessment of methods for testing the susceptibility of Haemophilus influenzae to clarithromycin.

A. Barry, P. Fuchs, S. Brown, 1996, The Journal of antimicrobial chemotherapy.

In vitro activity of the new ketolide HMR 3004 compared to an azalide and macrolides against Streptococcus pneumoniae and Haemophilus influenzae.

A. Barry, P. Fuchs, S. Brown, 1997, European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology.

Relative Potency of Telithromycin, Azithromycin and Erythromycin Against Recent Clinical Isolates of Gram-Positive Cocci

A. Barry, P. Fuchs, S. Brown, 2001, European Journal of Clinical Microbiology and Infectious Diseases.

Influence of Variations in Test Methods on Susceptibility of Haemophilus influenzae to Ampicillin, Azithromycin, Clarithromycin, and Telithromycin

Steven D. Brown, A. Barry, P. Fuchs, 2001, Journal of Clinical Microbiology.

Macrolide resistance among Streptococcus pneumoniae and Streptococcus pyogenes isolates from out-patients in the USA.

A. Barry, P. Fuchs, S. Brown, 1997, The Journal of antimicrobial chemotherapy.

In vitro bactericidal activity of daptomycin against staphylococci.

Steven D. Brown, A. Barry, P. Fuchs, 2002, The Journal of antimicrobial chemotherapy.

In Vitro Activities of Daptomycin against 2,789 Clinical Isolates from 11 North American Medical Centers

Steven D. Brown, A. Barry, P. Fuchs, 2001, Antimicrobial Agents and Chemotherapy.

In vitro activity and selection of disk content for disk diffusion susceptibility tests with trovafloxacin

A. Barry, P. Fuchs, S. Brown, 1996, European Journal of Clinical Microbiology and Infectious Diseases.

Multicenter in vitro evaluation of lomefloxacin (NY-198, SC-47111), including tests against nearly 7,000 bacterial isolates and preliminary recommendations for susceptibility testing.

R. Jones, J. Washington, K. Aldridge, 1988, Diagnostic microbiology and infectious disease.

The Replicator Method for Identification and Biotyping of Common Bacterial Isolates

P. Fuchs, 1975 .

In vitro activities of sparfloxacin, tosufloxacin, ciprofloxacin, and fleroxacin

A. Barry, P. Fuchs, Peter C. Fuchs, 1991, Antimicrobial Agents and Chemotherapy.

Cefotetan, a new cephamycin: comparison of in vitro antimicrobial activity with other cephems, beta-lactamase stability, and preliminary recommendations for disk diffusion testing

L. Ayers, R. Jones, A. Barry, 1982, Antimicrobial Agents and Chemotherapy.

Ofloxacin susceptibility testing quality control parameters for microdilution and disk diffusion, and confirmation of disk diffusion interpretive criteria

R. Jones, A. Barry, P. Fuchs, 1989, Journal of clinical microbiology.

Selection of a reference lot of Mueller-Hinton agar

A. Barry, P. Fuchs, H. Frankel, 1986, Journal of clinical microbiology.

Ceftizoxime and cefoxitin susceptibility testing against anaerobic bacteria: comparison of results from three NCCLS methods and quality control recommendations for the reference agar dilution procedure.

R. Jones, A. Barry, P. Fuchs, 1987, Diagnostic microbiology and infectious disease.

Antimicrobial activity of cefmetazole (CS-1170) and recommendations for susceptibility testing by disk diffusion, dilution, and anaerobic methods

R. Jones, A. Barry, P. Fuchs, 1986, Journal of clinical microbiology.

Antimicrobial susceptibility tests with cefotaxime and correlation with clinical bacteriologic response.

R. Jones, A. Barry, P. Fuchs, 1982, Reviews of infectious diseases.

Cefotaxime: in vitro activity and tentative interpretive standards for disk susceptibility testing

R. Jones, A. Barry, P. Fuchs, 1980, Antimicrobial Agents and Chemotherapy.

Disk diffusion susceptibility testing of two macrolide antimicrobial agents: revised interpretive criteria for erythromycin and preliminary guidelines for roxithromycin (RU 965)

R. Jones, A. Barry, P. Fuchs, 1986, Journal of clinical microbiology.

Quality control limits for ampicillin, carbenicillin, mezlocillin, and piperacillin disk diffusion susceptibility tests: a collaborative study

L. Reller, R. Jones, A. Barry, 1981, Journal of clinical microbiology.

Statistical criteria for selecting quality control limits for broth microdilution susceptibility tests with 39 different antimicrobial agents. Collaborative Antimicrobial Susceptibility Testing Group.

R. Jones, A. Barry, P. Fuchs, 1989, Diagnostic microbiology and infectious disease.

RO 23-6240 (AM-833), a new fluoroquinolone: in vitro antimicrobial activity and tentative disk diffusion interpretive criteria.

Ronald N. Jones, L. Ayers, R. Jones, 1987, Diagnostic microbiology and infectious disease.

Cross-resistance and cross-susceptibility between fluoroquinolone agents

A. Barry, P. Fuchs, 1991, European Journal of Clinical Microbiology and Infectious Diseases.

In vitro activity of DJ-6783 (a keto carboxylic acid) compared with six other orally administered antimicrobial agents.

L. Ayers, R. Jones, A. Barry, 1986, Diagnostic microbiology and infectious disease.

Evaluation of in vitro antibacterial activity of enoxacin: comparison with other orally absorbed antimicrobial agents, proposed disk diffusion test interpretive criteria, and quality control limits.

R. Jones, A. Barry, P. Fuchs, 1985, Diagnostic microbiology and infectious disease.

Multilaboratory evaluation of an agar diffusion disk susceptibility test for rapidly growing anaerobic bacteria.

R. Jones, K. Aldridge, A. Bourgault, 1990, Reviews of infectious diseases.

An in vitro evaluation of HRE 664, a novel penem antibiotic.

R. Jones, K. Aldridge, A. Barry, 1988, Diagnostic microbiology and infectious disease.

Evaluation of in vitro methods for testing susceptibility of anaerobes to ampicillin-sulbactam and amoxicillin-clavulanic acid

R. Jones, A. Barry, P. Fuchs, 1988, Journal of clinical microbiology.

Stability of antimicrobials in Schaedler's anaerobic and brain heart infusion broths stored at --20 degrees C.

R. Jones, A. Barry, P. Fuchs, 1978, The Journal of antibiotics.

Moxalactam (LY127935), a new semisynthetic 1-oxa-beta-lactam antibiotic with remarkable antimicrobial activity: in vitro comparison with cefamandole and tobramycin

R. Jones, A. Barry, P. Fuchs, 1980, Antimicrobial Agents and Chemotherapy.

Influence of the test medium on azithromycin and erythromycin regression statistics

A. Barry, P. Fuchs, 1991, European Journal of Clinical Microbiology and Infectious Diseases.

Quality control limits for the standard anaerobic reference agar dilution susceptibility test procedure of the National Committee for Clinical Laboratory Standards

R. Jones, A. Barry, P. Fuchs, 1989, Journal of clinical microbiology.

Ceftizoxime: collaborative multiphased in-vitro evaluation including tentative interpretive standards for disc susceptibility tests, beta-lactamase stability, and inhibition.

R. Jones, A. Barry, P. Fuchs, 1982, The Journal of antimicrobial chemotherapy.

Cefoperazone (T-1551), a new semisynthetic cephalosporin: comparison with cephalothin and gentamicin

R. Jones, A. Barry, P. Fuchs, 1980, Antimicrobial Agents and Chemotherapy.

Piperacillin (T-1220), a new semisynthetic penicillin: in vitro antimicrobial activity comparison with carbenicillin, ticarcillin, ampicillin, cephalothin, cefamandole and cefoxitin.

R. Jones, A. Barry, P. Fuchs, 1977, The Journal of antibiotics.

Antimicrobic susceptibility and plasmid profile analysis as identity tests for multiple blood isolates of coagulase-negative staphylococci

J. H. Crosa, M. Valvano, S. Potter, 1987, Journal of clinical microbiology.

Disk diffusion susceptibility testing of ticarcillin plus clavulanic acid

R. Jones, A. Barry, P. Fuchs, 1984, Journal of clinical microbiology.

Ceftazidime, a pseudomonas-active cephalosporin: in-vitro antimicrobial activity evaluation including recommendations for disc diffusion susceptibility tests.

R. Jones, A. Barry, P. Fuchs, 1981, The Journal of antimicrobial chemotherapy.

Antistaphylococcal activity of the fluoroquinolones CI-960, PD 131628, sparfloxacin, ofloxacin and ciprofloxacin

A. Barry, P. Fuchs, 1991, European Journal of Clinical Microbiology and Infectious Diseases.

Antimicrobial activity of Ro 15-8074, active metabolite of a new oral cephalosporin (Ro 15-8075), against 7,775 recent clinical isolates

L. Ayers, R. Jones, A. Barry, 1986, Antimicrobial Agents and Chemotherapy.

The impact of proficiency survey programs on laboratory antimicrobial susceptibility testing

Ronald N. Jones, P. Fuchs, 1984 .

Cefmenoxime (SCE-1365), a new Cephalosporin: In Vitro Activity, Comparison with Other Antimicrobial Agents, Beta-Lactamase Stability, and Disk Diffusion Testing with Tentative Interpretive Criteria

Ronald N. Jones, A. Barry, P. Fuchs, 1981, Antimicrobial Agents and Chemotherapy.

Relative efficacy of tazobactam, sulbactam and clavulanic acid in enhancing the potency of ampicillin against clinical isolates ofEnterobacteriaceae

D. Hardy, P. Fuchs, M. Pfaller, 1993, European Journal of Clinical Microbiology and Infectious Diseases.

Comparison of fixed concentration and fixed ratio options for testing susceptibility of gram-negative bacilli to piperacillin and piperacillin/tazobactam

D. Hardy, A. Barry, P. Fuchs, 1992, European Journal of Clinical Microbiology and Infectious Diseases.

Evaluation of the in vitro activity of BMY-28142, a new broad-spectrum cephalosporin

R. Jones, A. Barry, P. Fuchs, 1985, Antimicrobial Agents and Chemotherapy.

Evaluation of disk susceptibility testing of cefotaxime/desacetylcefotaxime.

R. Jones, A. Barry, P. Fuchs, 1989, Diagnostic microbiology and infectious disease.

Desacetylcefotaxime--another broad spectrum cephalosporin?

L. Ayers, R. Jones, A. Barry, 1989, The Journal of antimicrobial chemotherapy.

Survey of antimicrobial activity of four commonly used third generation cephalosporins tested against recent bacterial isolates from ten American medical centers, and assessment of disk diffusion test performance. AST Surveillance Group.

A. Barry, P. Fuchs, S. Brown, 1996, Diagnostic microbiology and infectious disease.

Temocillin: in vitro activity against 734 selected clinical isolates, including beta-lactamase-producing strains.

R. Jones, A. Barry, P. Fuchs, 1984, Diagnostic microbiology and infectious disease.

In vitro evaluation of Augmentin by broth microdilution and disk diffusion susceptibility testing: regression analysis, tentative interpretive criteria, and quality control limits

A L Barry, R N Jones, T L Gavan, 1983, Antimicrobial Agents and Chemotherapy.

BL-S786, a new parenteral cephalosporin. II. In vitro antimicrobial activity comparison with six related cephalosporins.

R. Jones, A. Barry, P. Fuchs, 1977, The Journal of antibiotics.

Comparison of Amino Acid Decarboxylase and Dihydrolase Results by Moeller, Rapid, and Replicator Plate Methods

Ronald N. Jones, P. Fuchs, Steve Sniderman, 1976, Journal of clinical microbiology.

Indwelling intravenous polyethylene catheters. Factors influencing the risk of microbial colonization and sepsis.

P. Fuchs, 1971, JAMA.

Comparative in vitro antimicrobial activity of a new carbapenem, E1010, and tentative disc diffusion test interpretative criteria.

A. Barry, P. Fuchs, S. Brown, 2001, The Journal of antimicrobial chemotherapy.

The gonococcus and the toilet seat.

P. Fuchs, J. Gilbaugh, 1979, The New England journal of medicine.

Multiple-Inocula (Replicator) CAMP Test for Presumptive Identification of Group B Streptococci

Ronald N. Jones, P. Fuchs, Carol Christy, 1978, Journal of clinical microbiology.

Antibacterial Activity of Moxifloxacin (Bay 12-8039) against Aerobic Clinical Isolates, and Provisional Criteria for Disk Susceptibility Tests

A. Barry, P. Fuchs, S. Brown, 1999, European Journal of Clinical Microbiology and Infectious Diseases.

In vitro inactivation of aminoglycosides by sulbactam, other beta-lactams, and sulbactam-beta-lactam combinations

A. Barry, P. Fuchs, P. Anderson, 1991, Antimicrobial Agents and Chemotherapy.

In vitro susceptibility testing procedures for fosfomycin tromethamine

A. Barry, P. Fuchs, 1991, Antimicrobial Agents and Chemotherapy.

Selection of Zone Size Interpretive Criteria for Disk Diffusion Susceptibility Tests of Three Antibiotics against Streptococcus pneumoniae, Using the New Guidelines of the National Committee for Clinical Laboratory Standards

Steven D. Brown, A. Barry, P. Fuchs, 2002, Antimicrobial Agents and Chemotherapy.

Piperacillin/tazobactam (YTR 830) combination. Comparative antimicrobial activity against 5889 recent aerobic clinical isolates and 60 Bacteroides fragilis group strains.

R. Jones, K. Aldridge, P. Fuchs, 1989, Diagnostic microbiology and infectious disease.

Fluoroquinolone resistance among recent clinical isolates of Streptococcus pneumoniae.

A. Barry, P. Fuchs, S. Brown, 1999, The Journal of antimicrobial chemotherapy.

Antimicrobial activity of cefpirome. An update compared to five third-generation cephalosporins against nearly 6000 recent clinical isolates from five medical centers.

R. Jones, K. Aldridge, P. Fuchs, 1991, Diagnostic microbiology and infectious disease.

Susceptibilities of beta-lactamase-producing and -nonproducing ampicillin-resistant strains of Haemophilus influenzae to ceftibuten, cefaclor, cefuroxime, cefixime, cefotaxime, and amoxicillin-clavulanic acid

A. Barry, P. Fuchs, M. Pfaller, 1993, Antimicrobial Agents and Chemotherapy.

Fortimicin A: collaborative in vitro susceptibility. Comparison with amikacin and gentamicin against 11,840 clinical bacterial isolates

R. Jones, A. Barry, P. Fuchs, 1979, Antimicrobial Agents and Chemotherapy.

In vitro activity of gemifloxacin against contemporary clinical bacterial isolates from eleven North American medical centers, and assessment of disk diffusion test interpretive criteria.

A. Barry, P. Fuchs, S. Brown, 2000, Diagnostic microbiology and infectious disease.

1-N-(S-3-amino-2-hydroxypropionyl) gentamicin B (Sch 21420): A collaborative in vitro susceptibility comparison with amikacin and gentamicin against 12,984 clinical bacterial isolates

Ronald N. Jones, A. Barry, P. Fuchs, 1978, Current Microbiology.

Ticarcillin: a collaborative in vitro comparison with carbenicillin against over 9,000 clinical bacterial isolates

R. Jones, A. Barry, P. Fuchs, 1977, The American journal of the medical sciences.

BL-S786, A NEW PARENTERAL CEPHALOSPORIN. I

Ronald N. Jones, A. Barry, P. Fuchs, 1977 .

Prevalence of resistance to three fluoroquinolones: assessment of levofloxacin disk test error rates and surrogate predictors of levofloxacin susceptibility. AST Surveillance Group

A. Barry, P. Fuchs, S. Brown, 1996, Antimicrobial agents and chemotherapy.

Methods for testing the susceptibility of anaerobic bacteria to two fluoroquinolone compounds, PD 131628 and clinafloxacin.

D. Citron, A. Barry, P. Fuchs, 1993, The Journal of antimicrobial chemotherapy.

Cefpiramide: comparative in-vitro activity and beta-lactamase stability.

Ronald N. Jones, L. Ayers, R. Jones, 1985, The Journal of antimicrobial chemotherapy.

In vitro antimicrobial activity and susceptibility testing of ofloxacin. Current status.

P. Fuchs, 1989, The American journal of medicine.

Cefaclor and cefatrizine, new investigational orally administered cephalosporins. In-vitro collaborative evaluation against clinical bacterial isolates and comparison with related antimicrobics.

R. Jones, A. Barry, P. Fuchs, 1979, American journal of clinical pathology.

Rosamicin: in vitro activity comparison with erythromycin and other antibiotics against clinical isolates from the genito-urinary tract and Neisseria meningitidis.

R. Jones, A. Barry, P. Fuchs, 1979, The Journal of antibiotics.

Disk diffusion testing, quality control guidelines, and antimicrobial spectrum of HR810, a fourth-generation cephalosporin, in clinical microbiology laboratories

L. Ayers, R. Jones, A. Barry, 1984, Journal of clinical microbiology.

Tentative criteria for confirming the in vitro susceptibilities of Haemophilus influenzae and Neisseria gonorrhoeae to two fluoroquinolones (sparfloxacin and levofloxacin), including quality control parameters

P. Murray, F. Tenover, J. Jorgensen, 1993, Journal of clinical microbiology.

Proposed interpretive criteria and quality control parameters for ofloxacin susceptibility testing of Neisseria gonorrhoeae

P. Murray, J. Washington, A. Barry, 1992, Journal of clinical microbiology.

Synovial histology in carpal tunnel syndrome.

L. D. Myers, P. Nathan, P. Fuchs, 1991, The Journal of hand surgery.

PMX-622 (Polymyxin B-Dextran 70) Does Not Alter In Vitro Activities of 11 Antimicrobial Agents

Steven D. Brown, A. Barry, P. Fuchs, 1998, Antimicrobial Agents and Chemotherapy.

Antimicrobial activity and spectrum of cefoperazone against recent clinical isolates.

R. Jones, A. Barry, P. Fuchs, 1980, Clinical therapeutics.

Comparison of In Vitro Antimicrobial Activity of Cefamandole and Cefazolin with Cephalothin Against over 8,000 Clinical Bacterial Isolates

Ronald N. Jones, P. Fuchs, 1976, Antimicrobial Agents and Chemotherapy.

Cefuroxime, an in vitro Comparison with Six Other Cephalosporins

R. Jones, A. Barry, P. Fuchs, 1977, Proceedings of the Royal Society of Medicine.

In vitro activity of ampicillin, amoxicillin, ampicillin-sulbactam, and amoxicillin-clavulanic acid against consecutive clinical isolates of Enterobacteriaceae.

D. Hardy, A. Barry, P. Fuchs, 1993, Diagnostic microbiology and infectious disease.

Streptococcus pneumoniae killing rate and post-antibiotic effect of levofloxacin and ciprofloxacin.

A. Barry, P. Fuchs, S. Brown, 1997, Journal of chemotherapy.

Daptomycin susceptibility tests: interpretive criteria, quality control, and effect of calcium on in vitro tests.

Steven D. Brown, A. Barry, P. Fuchs, 2000, Diagnostic microbiology and infectious disease.

Evaluation of daptomycin susceptibility testing by Etest and the effect of different batches of media.

A. Barry, P. Fuchs, S. Brown, 2001, The Journal of antimicrobial chemotherapy.

Multicenter survey of the in vitro activity of four expanded-spectrum beta-lactams against consecutive contemporary clinical isolates.

A. Barry, P. Fuchs, S. Brown, 1998, Diagnostic microbiology and infectious disease.

Quality control limits for microdilution susceptibility tests with aztreonam, imipenem, ceftriaxone, ceftazidime, ceftizoxime, cefuroxime, and cefonicid.

L. Ayers, R. Jones, A. Barry, 1987, Diagnostic microbiology and infectious disease.

Activity of cefepime (BMY-28142) and cefpirome (HR 810) against gram-negative bacilli resistant to cefotaxime or ceftazidime.

R. Jones, P. Fuchs, Peter C. Fuchs, 1989, The Journal of antimicrobial chemotherapy.

In vitro activity of carumonam (RO 17-2301), BMY-28142, aztreonam, and ceftazidime against 7,620 consecutive clinical bacterial isolates.

L. Ayers, R. Jones, A. Barry, 1986, Diagnostic microbiology and infectious disease.

Cefixime Disk Susceptibility Test Criteria

R. Jones, A. Barry, P. Fuchs, 1987, Journal of clinical microbiology.

In vitro activity and disk susceptibility of Timentin: current status.

R. Jones, A. Barry, P. Fuchs, 1985, The American journal of medicine.

In-vitro activity of five β-lactam/β-lactamase inhibitor combinations against consecutive isolates of the Enterobacteriaceae and Pseudomonas aeruginosa

D. Hardy, A. Barry, P. Fuchs, 1994 .

Error rates in cefoperazone and cefoperazone-sulbactam disk tests withenterobacteriaceae andPseudomonas aeruginosa

D. Hardy, A. Barry, P. Fuchs, 1992, European Journal of Clinical Microbiology and Infectious Diseases.

In vitro antimicrobial activity of tigemonam, a new orally administered monobactam

R. Jones, A. Barry, P. Fuchs, 1988, Antimicrobial Agents and Chemotherapy.

Antimicrobial activity of U-76,252 (CS-807), a new orally administered cephalosporin ester, including recommendations for MIC quality control.

L. Ayers, R. Jones, A. Barry, 1988, Diagnostic microbiology and infectious disease.

Quality control limits for microdilution susceptibility tests with norfloxacin

L. Ayers, A. Barry, P. Fuchs, 1987, Journal of clinical microbiology.

Effect of clavulanic acid on the susceptibility of clinical anaerobic bacteria to ticarcillin: a multicenter study.

R. Jones, K. Aldridge, A. Barry, 1988, Diagnostic microbiology and infectious disease.

Effect of beta-lactamase inhibitors on the antimicrobial activity of cefoperazone, cefotaxime, and ceftizoxime against aerobic and anaerobic beta-lactamase producing bacteria.

R. Jones, A. Barry, P. Fuchs, 1987, Diagnostic microbiology and infectious disease.

Multilaboratory evaluation of the in vitro activity of 13 beta-lactam antibiotics against 1474 clinical isolates of aerobic and anaerobic bacteria.

P. Murray, R. Jones, P. Fuchs, 1993, Diagnostic microbiology and infectious disease.

In vitro activities of five fluoroquinolone compounds against strains of Streptococcus pneumoniae with resistance to other antimicrobial agents

A. Barry, P. Fuchs, S. Brown, 1996, Antimicrobial agents and chemotherapy.

Assessment of Catheter-Associated Infection Risk with the Hickman Right Atrial Catheter

P. Fuchs, M. Gustafson, P. T. Goodall, 1984, Infection Control.

Antimicrobial activity of Ro 19-5247 (T-2525), a new oral cephalosporin, tested against 7,745 recent clinical isolates.

L. Ayers, R. Jones, A. Barry, 1987, Diagnostic microbiology and infectious disease.

The antibacterial activity of co-amoxiclav.

A. Barry, P. Fuchs, M. Pfaller, 1993, The Journal of antimicrobial chemotherapy.

BL-S786, a new parenteral cephalosporin. I. A collaborative in vitro susceptibility comparison to cephalothin against 5,762 clinical bacterial isolates.

R. Jones, A. Barry, P. Fuchs, 1977, The Journal of antibiotics.

In Vitro Activities of Clinafloxacin against Contemporary Clinical Bacterial Isolates from 10 North American Centers

Steven D. Brown, A. Barry, P. Fuchs, 1998, Antimicrobial Agents and Chemotherapy.

Tentative disk diffusion susceptibility interpretive criteria for BMY-28142, a new cephalosporin

R. Jones, A. Barry, P. Fuchs, 1986, Journal of clinical microbiology.

Interpretive criteria, quality control guidelines, and drug stability studies for susceptibility testing of cefotaxime, cefoxitin, ceftazidime, and cefuroxime against Neisseria gonorrhoeae.

P. Murray, R. Jones, J. Washington, 1990, Diagnostic microbiology and infectious disease.

Multicenter evaluation of the in vitro activities of three new quinolones, sparfloxacin, CI-960, and PD 131,628, compared with the activity of ciprofloxacin against 5,252 clinical bacterial isolates

A. Barry, P. Fuchs, M. Pfaller, 1991, Antimicrobial Agents and Chemotherapy.

The anti-microbial activity, beta-lactamase stability, and disk diffusion susceptibility testing of carumonam (RO 17-2301, AMA-1080), a new monobactam.

R. Jones, A. Barry, P. Fuchs, 1986, American journal of clinical pathology.

Susceptibility of bacterial respiratory pathogens to amoxicillin and amoxicillin-clavulanic acid

A. Barry, P. Fuchs, Peter C. Fuchs, 1994, European Journal of Clinical Microbiology and Infectious Diseases.

Cefditoren in vitro activity and spectrum: a review of international studies using reference methods.

M. Pfaller, R. Jones, M. Jacobs, 2001, Diagnostic microbiology and infectious disease.

Interpretive criteria for antimicrobial susceptibility tests with cefodizime discs.

A. Barry, P. Fuchs, 1991, The Journal of antimicrobial chemotherapy.

Susceptibility of Streptococcus pneumoniae and Haemophilus influenzae to cefditoren, and provisional interpretive criteria.

A. Barry, P. Fuchs, S. Brown, 2000, Diagnostic microbiology and infectious disease.

Quality control parameters for cefditoren susceptibility tests.

A. Barry, P. Fuchs, S. Brown, 2001, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

Proposed interpretive criteria and quality control parameters for testing in vitro susceptibility of Neisseria gonorrhoeae to ciprofloxacin

P. Murray, J. Washington, A. Barry, 1991, Journal of clinical microbiology.

Proposed interpretive criteria and quality control parameters for testing susceptibility of Neisseria gonorrhoeae to beta-lactam-clavulanate combinations

P. Murray, J. Washington, A. Barry, 1992, Journal of clinical microbiology.

Is Escherichia coli ATCC 25922 useful for monitoring broth microdilution tests of fluoroquinolones?

A. Barry, P. Fuchs, S. Brown, 1997, The Journal of antimicrobial chemotherapy.

Antimicrobial activity and disk diffusion susceptibility testing of Ro 40-6890, the active metabolite of the new cephalosporin ester, Ro 41-3399

A. Barry, P. Fuchs, M. Pfaller, 1993, Antimicrobial Agents and Chemotherapy.

Mezlocillin: tentative interpretive standards for disk diffusion susceptibility testing

R. Jones, A. Barry, P. Fuchs, 1981, Antimicrobial Agents and Chemotherapy.

Spontaneously occurring staphylococcal mutants resistant to clinically achievable concentrations of ciprofloxacin and temafloxacin

A. Barry, P. Fuchs, M. Pfaller, 1992, European Journal of Clinical Microbiology and Infectious Diseases.

Tentative disk diffusion susceptibility interpretive criteria for pefloxacin

R. Jones, A. Barry, P. Fuchs, 1986, Journal of clinical microbiology.

Anti-staphylococcal activity of temafloxacin, ciprofloxacin, ofloxacin and enoxacin.

A. Barry, P. Fuchs, 1991, The Journal of antimicrobial chemotherapy.

Susceptibility testing quality control studies with fosfomycin tromethamine

A. Barry, P. Fuchs, S. Brown, 1997, European Journal of Clinical Microbiology and Infectious Diseases.

Fosfomycin tromethamine susceptibility of outpatient urine isolates of Escherichia coli and Enterococcus faecalis from ten North American medical centres by three methods.

A. Barry, P. Fuchs, S. Brown, 1999, The Journal of antimicrobial chemotherapy.

Interpretive criteria and quality control parameters for determining bacterial susceptibility to fosfomycin tromethamine

F. Tenover, L. Reller, D. Hardy, 1993, European Journal of Clinical Microbiology and Infectious Diseases.

Evaluation of disk susceptibility testing of fosfomycin tromethamine.

A. Barry, P. Fuchs, M. Pfaller, 1993, Diagnostic microbiology and infectious disease.

Pneumococcal susceptibility to meropenem.

A. Barry, P. Fuchs, S. Brown, 1996, The Journal of antimicrobial chemotherapy.

Interpretive criteria and quality control parameters for testing bacterial susceptibility to the fluoroquinolone PD131628

F. Tenover, L. Reller, J. Jorgensen, 1995, Journal of clinical microbiology.

Ticarcillin, carbenicillin and BL-P1908. In vitro comparison of three anti-pseudomonal semisynthetic penicillins.

R. Jones, A. Barry, P. Fuchs, 1977, The Journal of antibiotics.

In-vitro susceptibility of Streptococcus pneumoniae to the d- and l-isomers of ofloxacin: interpretive criteria and quality control limits.

F. Tenover, J. Jorgensen, A. Barry, 1996, The Journal of antimicrobial chemotherapy.

Reassessment of susceptibility test interpretive criteria for ticarcillin and ticarcillin-clavulanic acid

R. Jones, A. Barry, P. Fuchs, 1989, Journal of clinical microbiology.

Comparison of identification systems for Staphylococcus epidermidis and other coagulase-negative Staphylococcus species.

T. Perl, M. Pfaller, F. Koontz, 1994, Diagnostic microbiology and infectious disease.

Haemophilus test medium versus Mueller-Hinton broth with lysed horse blood for antimicrobial susceptibility testing of four bacterial species

A. Barry, P. Fuchs, M. Pfaller, 1993, European Journal of Clinical Microbiology and Infectious Diseases.

Relative potencies of azithromycin, clarithromycin and five other orally administered antibiotics.

A. Barry, P. Fuchs, S. Brown, 1995, The Journal of antimicrobial chemotherapy.

RO 23-9424, a new cephalosporin 3'-quinolone: in-vitro antimicrobial activity and tentative disc diffusion interpretive criteria.

A. Barry, P. Fuchs, M. Pfaller, 1993, The Journal of antimicrobial chemotherapy.

Dilemmas of the Beta-Lactam Explosion

R. Jones, P. Fuchs, 1981, Infection Control.

Ticarcillin and ticarcillin-clavulanic acid susceptibility tests: error rates for disk tests with consecutively isolated members of the family Enterobacteriaceae

D. Hardy, A. Barry, P. Fuchs, 1992, Antimicrobial Agents and Chemotherapy.

In-vitro potency of azithromycin against gram-negative bacilli is method-dependent.

A. Barry, P. Fuchs, 1991, Journal of Antimicrobial Chemotherapy.

Peter C. Fuchs, M.D. Reply

P. Fuchs, 1983, Infection Control.

Comparison of fixed concentration and fixed ratio options for dilution susceptibility testing of gram-negative bacilli to ampicillin and ampicillin/sulbactam

D. Hardy, A. Barry, P. Fuchs, 1993, European Journal of Clinical Microbiology and Infectious Diseases.

Susceptibility of Haemophilus influenzae to piperacillin-tazobactam combinations: interpretive criteria and quality control limits for standardized tests

F. Tenover, J. Jorgensen, D. Hardy, 1993, Journal of Clinical Microbiology.

Summary and analysis of the mycology proficiency testing survey results of the College of American Pathologists. 1976-1979.

P. Fuchs, C. Dolan, 1981, American journal of clinical pathology.

Quality control guidelines for testing cefotetan in the reference agar dilution procedure for susceptibility testing of anaerobic bacteria

R. Jones, A. Barry, P. Fuchs, 1989, Journal of clinical microbiology.

Evaluation of in vitro methods for testing susceptibility of anaerobes to ampicillin-sulbactam and amoxicillin-clavulanic acid

R. Jones, P. Fuchs, A. Barry, 1988, Journal of clinical microbiology.